Anavex Life Sciences Corp. (LON:0HFR)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 166.62M -69.1% |
| Revenue (ttm) | n/a |
| Net Income | -9.81M |
| EPS | -0.11 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 702 |
| Open | 2.330 |
| Previous Close | 2.330 |
| Day's Range | 2.330 - 2.390 |
| 52-Week Range | 2.270 - 10.460 |
| Beta | 1.14 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About Anavex Life Sciences
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ... [Read more]
News
Anavex Stockholders Elect All of the Company's Director Nominees at 2026 Annual Meeting
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central ...
PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders – -- Believes Anavex Needs New Leadership...
Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management's Call for Change
-- Proxy advisor recommends voting “ FOR” two of PVG's director nominees and “AGAINST” two incumbent director nominees including the board's current chair on the GOLD Universal Proxy Card –
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 15, 2026, providing details for shareholder voting and corporate governance matters.
PVG Asset Management Believes ISS Acknowledges Anavex's Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance
-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board's nominees –
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex's Highly Qualified Director Nominees
ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS' Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOB...
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
CENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ: AVXL) ("Anavex" or the "Company"), today announced that i...
Anavex Life Sciences Transcript: Status update
Regained Nasdaq compliance and addressed internal control weaknesses, with a renewed focus on transparency and disciplined execution. Prioritizing blarcamesine development for Alzheimer's, Rett syndrome, and Fragile X syndrome, while pausing other programs to concentrate resources.
PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)
CENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (Nasdaq: AVXL "Anavex" or the "Company"), believes the Anavex Boar...
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 8, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
PVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.'s 2026 Annual Meeting
CENTENNIAL, Colo., Sept. 01, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corporation (“PVG”), together with the other participants named below, has filed a definitive proxy statement on Schedule 14A...
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on September 1, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 31, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 27, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Clinical Development Strategy for Alzheimer's Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer's Disease Clinical Study Dat...
Anavex Life Sciences Earnings release: Q3 2026
Anavex Life Sciences released its Q3 2026 earnings on August 25, 2026, summarizing the period's financial results.
Anavex Life Sciences Quarterly report: Q3 2026
Anavex Life Sciences has published its Q3 2026 quarterly earnings report on August 25, 2026.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 17, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 17, 2026, providing details for shareholder voting and corporate governance matters.